You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
NEW YORK (360Dx) – After establishing its first two tests to predict the risk of metastasis in two melanoma indications, Castle Biosciences is laying the foundation to expand its technology for use in cutaneous squamous cell carcinoma (sCCC).
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.